Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod

Stavrakoglou, Anastasios; Brown, Victoria; Coutts, Ian

doi:10.1111/j.1365-2133.2007.07976.x

Cited by 13 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…102 In addition, anecdotal reports have also described successful imiquimod use in the treatment of rare MF variants such as pagetoid reticulosis 103 and other cutaneous lymphomas including CD30 + anaplastic large cell lymphoma, lymphomatoid papulosis, and primary cutaneous B-cell lymphomas. [104][105][106][107]…”

Section: Melanoma In Situmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. This allows its use for the treatment of a wide variety of benign and malignant skin conditions due to its potential antiviral, antitumor, and immunoregulatory effects. Currently, topical imiquimod is US Food and Drug Administration (FDA)-approved for the treatment of anogenital warts, actinic keratosis, and superficial basal cell carcinomas. However, it has also shown a beneficial effect in the treatment of many other skin disorders. In this review, we describe existing evidence on the mechanism of action of topical imiquimod, its FDA-approved indications, off-label uses, and side effects.

show abstract

Section: Melanoma In Situmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

show abstract

“…There are case reports showing the efficacy of topical therapy with using steroids, imiquimod, and nitrogen mustard or bexarotene gel. 375,[383][384][385][386] For patients presenting with generalized disease, the guidelines have included observation, rituximab, topical therapy, local RT, intralesional steroids, or systemic therapy (chlorambucil or CVP) with or without rituximab as options. In patients with very extensive or symptomatic disease, other chemotherapy regimens recommended for the treatment of FL may be used.…”

Section: Nccn Recommendationsmentioning

confidence: 99%

Non-Hodgkin's Lymphomas

Zelenetz

Abramson

Advani

et al. 2011

J Natl Compr Canc Netw

164

View full text Add to dashboard Cite

OverviewNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B-, T-, or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80% to 85% of the cases, with 15% to 20% being Tcell lymphomas; NK lymphomas are rare. In 2010, an estimated 65,540 new cases of NHL were diagnosed and 20,210 patients died of the disease.1 NHL is the sixth leading site of new cancer diagnoses among men and women, accounting for 4% of new cancer cases and 4% of cancer-related deaths.

show abstract

“…Imiquimod is a small biologically active molecule which acts via Toll‐like receptors to activate the innate immune system, inhibit angiogenesis and interfere with apoptosis 162–165 . Similarly to TCI, there is a growing off‐label use of imiquimod 4,166–175 . It appears to be effective in Kaposi’s sarcoma and Bowen’s disease (but further studies are needed to establish safety), and may be useful (under strict follow‐up) in patients with squamous cell carcinoma and lentigo maligna, who are unsuitable for more invasive procedures (Dr A. Peserico) 176 .…”

Section: Emerging Treatmentsmentioning

confidence: 99%

“…[162][163][164][165] Similarly to TCI, there is a growing off-label use of imiquimod. 4,[166][167][168][169][170][171][172][173][174][175] It appears to be effective in Kaposi's sarcoma and Bowen's disease (but further studies are needed to establish safety), and may be useful (under strict follow-up) in patients with squamous cell carcinoma and lentigo maligna, who are unsuitable for more invasive procedures (Dr A. Peserico). 176 There are also promising results for the treatment of infantile haemangiomas, morphoea and keloid scars (post-excision).…”

Section: Autoimmune and Inflammatory Skin Disordersmentioning

confidence: 99%

Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology

Alexandroff

Burd

2009

British Journal of Dermatology

View full text Add to dashboard Cite

The 17th Congress of the European Academy of Dermatology and Venereology took place in Paris on 17-20 September 2008 and brought together nearly 11,000 participants. Various plenary lectures, subspecialty meetings, 'free communications', 'top ten', 'test yourself' and 'junior' sessions, 19 courses and 14 'lunches with the expert', six forums, 27 symposia and 45 workshops were pressed into the 4 days of the meeting. Over 1700 posters were presented and exhibited. The themes of a number of symposiums, workshops and sessions overlapped, offering additional educational opportunities despite a very busy schedule. The meeting was well organized. Aesthetic dermatology comprised a significant part of the meeting. It is impossible to encompass all important presentations and we highlight a few medical pearls presented at the meeting; however, our report is not intended as a substitute for reading the conference proceedings and related references quoted in this article.

show abstract

Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod

Cited by 13 publications

References 7 publications

Imiquimod in dermatology: an overview

Imiquimod in dermatology: an overview

Non-Hodgkin's Lymphomas

Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology

Contact Info

Product

Resources

About